Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies
JAMA Oncol
.
2020 Feb 1;6(2):298-299.
doi: 10.1001/jamaoncol.2019.5148.
Authors
Shufang Liu
1
2
,
Wenquan Niu
3
Affiliations
1
Graduate School, Beijing University of Chinese Medicine, Beijing, China.
2
Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China.
3
Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
PMID:
31774455
DOI:
10.1001/jamaoncol.2019.5148
No abstract available
Publication types
Letter
Comment
MeSH terms
B7-H1 Antigen
Biomarkers
Humans
Immunotherapy
Lung Neoplasms*
Programmed Cell Death 1 Receptor*
Substances
B7-H1 Antigen
Biomarkers
Programmed Cell Death 1 Receptor